In compliance with the National Institutes of Health Office of Science Policy (NIH OSP), MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC) to review, approve and confirm that the company’s research involving recombinant/synthetic DNA complies with NIH guidelines.
NIH IBC Meeting Schedule for March 31 @ MiraVista Diagnostics
The third meeting of the NIH approved IBC (Institutional Biosafety Committee) is scheduled for Tuesday, March 31, 2018 at 11:30 a.m. ET at MiraVista Diagnostics’ laboratory in Indianapolis, Indiana. Minutes from the committee meeting will be provided upon request once they are available. Please email requests to: firstname.lastname@example.org
MiraVista Diagnostics’ approved registration with NIH OSP IBC: https://ibc-rms.od.nih.gov/Contents/IBC_LIST_REPORT.aspx
NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules: https://osp.od.nih.gov/biotechnology/nih-guidelines/
NIH’s Biosafety and Recombinant DNA Policy Program overview: https://osp.od.nih.gov/biotechnology/biosafety-and-recombinant-dna-activities/